<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03981588</url>
  </required_header>
  <id_info>
    <org_study_id>PIE14/00066</org_study_id>
    <nct_id>NCT03981588</nct_id>
  </id_info>
  <brief_title>Cardiotoxicity in the Elderly</brief_title>
  <acronym>CARTIER</acronym>
  <official_title>CARDIOTOXICITY IN THE ELDERLY</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AORTICA Group</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Instituto de Investigación Biomédica de Salamanca</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>AORTICA Group</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      CARTIER (Cardiotoxicity in the elderly) is a prospective cohort study of newly diagnosed&#xD;
      elderly cancer patients equal or greater than 65 years of age conduced in one tertiary center&#xD;
      (Hospital Universitario de Salamanca at Spain. The study is academically funded in its&#xD;
      integrity by The Instituto de Salud Carlos III (Spanish Ministry of Science, Innovation and&#xD;
      Universities). The investigators of the study are the only responsible for the study design,&#xD;
      data collection, and data interpretation. All study participants provide written informed&#xD;
      consent. All enrolled patients will undergo serial surveys, 6-minutes walking test (6MWT),&#xD;
      electrocardiogram, echocardiogram, blood samples, CMR, physical examinations and&#xD;
      multidisciplinary clinical evaluations; before each chemotherapy cycle and at 3, 6, 9 and 12&#xD;
      months, 3 years and 5 years after finalization of chemotherapy, except for MRI that will be&#xD;
      performed before 1st, 3rd, 5th cycles and at 3, 6, 9,12 months, 3 years and 5 years after&#xD;
      chemotherapy ending&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Surveys completion and examinations will be obtained at the same day: within 72 hours before&#xD;
      each cycle of treatment or at 3, 6, 9, 12 months, 3 years and 5 years' follow-up after ending&#xD;
      the whole antitumoral course of treatment. A fully dedicated research nurse will play a vital&#xD;
      role in ensuring that the study run smoothly and that all participants will be safe and fully&#xD;
      informed. Questionnaires completion and quality of life assessment will initially be&#xD;
      performed followed by the 6MWT. Participants blood pressure measurement, electrocardiogram&#xD;
      and echocardiogram will be then taken &gt;30 minutes after finishing the walking test. Blood&#xD;
      sample extraction will be performed after echocardiography to finalize with cardiac magnetic&#xD;
      resonance. A complete medical history, physical examination and evaluation of these&#xD;
      examinations for each participant will be performed by a cardiologist at the cardio-oncology&#xD;
      unit, where prevention and treatment protocols for cardiotoxicity will be applied and&#xD;
      discussed in a multidisciplinary way with referral oncologists and hematologists before every&#xD;
      cycle of treatment and after course of antitumoral ending follow-up.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">March 2015</start_date>
  <completion_date type="Anticipated">March 2022</completion_date>
  <primary_completion_date type="Actual">December 2016</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>5 Years</target_duration>
  <primary_outcome>
    <measure>Incidence of cardiotoxicity</measure>
    <time_frame>5 years</time_frame>
    <description>53% as the lower limit of ejection fraction regardless of gender</description>
  </primary_outcome>
  <enrollment type="Actual">110</enrollment>
  <condition>Cardiotoxicity</condition>
  <condition>Elderly</condition>
  <condition>Cardiac Magnetic Resonance</condition>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Imaging studies</intervention_name>
    <description>Patients will undergo different imaging and clinical follow-up procedures to run out cardiotoxicity</description>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Blood samples&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Elderly patients with newly diagnosed cancer initiating antisudoral treatment&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  newly diagnosed cancer initiating antisudoral treatment&#xD;
&#xD;
          -  capability to sign the informed consent&#xD;
&#xD;
          -  capability to realize 6 minutes walking test&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  previous chemotherapy&#xD;
&#xD;
          -  contraindications to undergo cardiac magnetic resonance (CMR)&#xD;
&#xD;
          -  enrollment in onco-hematologist current clinical-trials&#xD;
&#xD;
          -  clinical situation making difficult the realization of the proposed examinations or&#xD;
             the course of chemotherapy.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>65 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Hospital Universitario de Salamanca</name>
      <address>
        <city>Salamanca</city>
        <zip>37002</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pedro Dorado</name>
      <address>
        <city>Salamanca</city>
        <zip>37007</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>June 2019</verification_date>
  <study_first_submitted>June 6, 2019</study_first_submitted>
  <study_first_submitted_qc>June 8, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">June 11, 2019</study_first_posted>
  <last_update_submitted>May 26, 2020</last_update_submitted>
  <last_update_submitted_qc>May 26, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 27, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>AORTICA Group</investigator_affiliation>
    <investigator_full_name>Pedro L Sanchez</investigator_full_name>
    <investigator_title>Head of the Cardiology Department</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cardiotoxicity</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

